TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16787141

Group type: EXPERIMENTAL
Intervention: Anti-VEGF drugs
Number of subjects: 0
Study: 12756363

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repair at diameter <5.5 cm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repair at larger diameter
Number of subjects: 0
Study: 11014755

Group type: EXPERIMENTAL
Intervention: AARN rucksack
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Traditional rucksack
Number of subjects: 9

Group type: COMPARATOR
Intervention: Unloaded walking
Number of subjects: 9
Study: 8781854

Group type: EXPERIMENTAL
Intervention: 5000 kJ.24 h‐1 additional energy in course A
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moderate continuous aerobic physical activities
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control response
Number of subjects: 8
Study: 1595785

Group type: EXPERIMENTAL
Intervention: Low-dose heparin plus low-dose aspirin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisone (40 mg daily) plus low-dose aspirin
Number of subjects: 20
Study: 3883732

Group type: EXPERIMENTAL
Intervention: oral molsidomine (Corvaton, 6 mg/day)
Number of subjects: 25
Study: 29490959

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every 3 weeks (taper arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (withdrawal arm)
Number of subjects: 0
Study: 27041257

Group type: EXPERIMENTAL
Intervention: Midazolam and acetaminophen (n = 38)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Acetaminophen only (n = 32)
Number of subjects: 70
Study: 24508292

Group type: EXPERIMENTAL
Intervention: Appearance-based video education
Number of subjects: 50

Group type: COMPARATOR
Intervention: Health-based video education
Number of subjects: 50
Study: 22520863

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) for AECOPD administered twice daily over 7 to 21 days, followed by TCM for AECOPD-RW over 28 days.
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control group (placebo) receiving medication according to assigned group.
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: TCM for AECOPD and AECOPD-RW.
Number of subjects: 364
Study: 20150290

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 1229

Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 1229
Study: 18560257

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study: 16421496

Group type: EXPERIMENTAL
Intervention: Electronic portal imaging (EPI) with online field realignment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no online beam realignment)
Number of subjects: 14
Study: 12046488

Group type: EXPERIMENTAL
Intervention: Moisturizer containing 10% urea and 4% lactic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 40
Study: 10452633

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg daily)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 149
Study: 7792376

Group type: EXPERIMENTAL
Intervention: Guided imagery preparation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Background information about the hospital (Control)
Number of subjects: 51
Study: 2198918

Group type: EXPERIMENTAL
Intervention: 600 mg of oral mifepristone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 318958

Group type: EXPERIMENTAL
Intervention: Ammonium fluoride rinse (1,000 parts/10(6) solution at pH 4.4)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sodium fluoride rinse (1,000 parts/10(6) solution at pH 4.4)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 30709391

Group type: EXPERIMENTAL
Intervention: Treatment as usual plus activation therapy (AT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 28911934

Group type: EXPERIMENTAL
Intervention: Dienogest (DNG) 2 mg/d, orally for 16 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 25529904

Group type: EXPERIMENTAL
Intervention: Infliximab (TNF antagonist)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23651847

Group type: EXPERIMENTAL
Intervention: Exercise training for 16 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 13
Study: 21412057

Group type: EXPERIMENTAL
Intervention: EVG/COBI/FTC/TDF
Number of subjects: 71

Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 71
Study: 19469829

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 17424753

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both drugs (1.5 x ED95)
Number of subjects: 60
Study: 10807113

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) 20 mg bid for 9 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo bid for 9 months
Number of subjects: 190
Study: 8634730

Group type: EXPERIMENTAL
Intervention: Intervention group (AIDS-risk reduction intervention)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 383
Study: 1996758

Group type: EXPERIMENTAL
Intervention: Air alone with spontaneous respiration
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Air supplemented with 1 or 4 litres/minute of oxygen
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Artificial ventilation with air alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Spontaneous respiration with at least 0.5 litres/minute of oxygen
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure ventilation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Air anaesthesia with spontaneous ventilation
Number of subjects: 36
Study: 6337671

Group type: EXPERIMENTAL
Intervention: Haemorrhoidectomy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Maximal anal dilation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Elastic band ligation
Number of subjects: 112
Study: 30557850

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Vandetanib 150 mg daily
Number of subjects: 81
Study: 29684316

Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Week 1 adherence
Number of subjects: 138
Study: 27698558

Group type: EXPERIMENTAL
Intervention: Combined physical and cognitive training (aerobic and resistance training + dual-task training)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Aerobic-strength condition
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Dual-task (DT) training
Number of subjects: 76

Group type: COMPARATOR
Intervention: Stretching and toning exercises (active control)
Number of subjects: 76
Study: 25315126

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.5 mg·ml(‐1), 1 ml·kg(‐1) mixed with 50 mg of magnesium (Group RM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine 1.5 mg·ml(‐1), 1 ml·kg(‐1) (Group R)
Number of subjects: 80
Study: 22570185

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard single-dose methotrexate treatment
Number of subjects: 90
Study: 20026785

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1500 mg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: HDL from healthy subjects (n=10)
Number of subjects: 33
Study: 17850370

Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Biopsy status (positive or negative)
Number of subjects: 40
Study: 16602327

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (group A)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Continuous oral antihistamine (cetirizine) treatment (group B)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oral antihistamine (cetirizine) on demand (group C)
Number of subjects: 31
Study: 11929078

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10432474

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus interpersonal psychotherapy (IPT + FLU)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy alone (IPT)
Number of subjects: 23
Study: 7569269

Group type: EXPERIMENTAL
Intervention: Pravastatin (HMG CoA reductase inhibitor), dosage and duration not specified
Number of subjects: 0
Study: 2404502

Group type: EXPERIMENTAL
Intervention: Extended-release felodipine tablets once daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Conventional felodipine tablets twice daily
Number of subjects: 147
Study: 31246662

Group type: EXPERIMENTAL
Intervention: Corticocancellous particulate allograft (Mineross) mixed with autogenous bone chips (70:30)
Number of subjects: 14

Group type: COMPARATOR
Intervention: DBM (Optecure‐CCC)
Number of subjects: 14
Study: 30379826

Group type: EXPERIMENTAL
Intervention: Evocalcet 0.5 mg/day
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Evocalcet 1 mg/day
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Evocalcet 2 mg/day
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cinacalcet 25 mg/day
Number of subjects: 152
Study: 27627194

Group type: EXPERIMENTAL
Intervention: Single-dose 175 mg omarigliptin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single-dose 25 mg omarigliptin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single-dose 400 mg moxifloxacin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (days 1 and 2)
Number of subjects: 60
Study: 24955738

Group type: EXPERIMENTAL
Intervention: Telemedicine system for grading retinal images by non-physician readers
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Diagnostic examination (DE) performed by experienced ophthalmologists
Number of subjects: 2000
Study: 22968888

Group type: EXPERIMENTAL
Intervention: Physician assessment-based adjustment
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Biomarker-based (exhaled nitric oxide) adjustment
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Symptom-based adjustment
Number of subjects: 342
Study: 20335355

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 60
Study: 17617525

Group type: EXPERIMENTAL
Intervention: Fertility‐sparing surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (bleomycin, etoposide, cisplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum cytoreductive surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surveillance strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second‐look surgery
Number of subjects: 0
Study: 16195045

Group type: EXPERIMENTAL
Intervention: Jump condition
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Run-up plus jump condition
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Run-up condition
Number of subjects: 7
Study: 12454315

Group type: EXPERIMENTAL
Intervention: Combination therapy (e.g., paclitaxel/trastuzumab or capecitabine/docetaxel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential therapy
Number of subjects: 0
Study: 10361111

Group type: EXPERIMENTAL
Intervention: Intermediate serum hyaluronan (HYA) values (10 to 120 micrograms/L)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Abnormally low HYA values (0 to 9 micrograms/L)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: High HYA values (>120 micrograms/L)
Number of subjects: 386
Study: 7595711

Group type: EXPERIMENTAL
Intervention: rhIL‐6 at 10.0 micrograms/kg/d
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: rhIL‐6 at 20.0 micrograms/kg/d
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: rhIL‐6 at various doses
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: rhIL‐6 at 10.0 and 20.0 micrograms/kg/d
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: rhIL‐6
Number of subjects: 19
Study: 2405628

Group type: EXPERIMENTAL
Intervention: Low-dose warfarin (average daily dose of 4.6 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of low-dose warfarin and low-dose aspirin
Number of subjects: 0
Study: 6966720

Group type: EXPERIMENTAL
Intervention: Travenol microporous polypropylene membrane oxygenator
Number of subjects: 64

Group type: COMPARATOR
Intervention: Bentley Q-100 bubble oxygenator
Number of subjects: 64
Study: 31722381

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional dual‐chamber pacing with algorithms for right ventricular pacing avoidance (DDD‐VPA)
Number of subjects: 82
Study: 31104819

Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (CH)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study: 27161806

Group type: EXPERIMENTAL
Intervention: Measured glomerular filtration rate (GFR) decline
Number of subjects: 101
Study: 25873338

Group type: EXPERIMENTAL
Intervention: Alternative format of Summary-of-Findings tables (Table A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standard format of Summary-of-Findings tables (Table C)
Number of subjects: 0
Study: 23515127

Group type: EXPERIMENTAL
Intervention: Internal fixation (IF) using 2 cannulated screws
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cemented hemiarthroplasty (HA) using a cemented Exeter unipolar arthroplasty
Number of subjects: 60
Study: 21075644

Group type: EXPERIMENTAL
Intervention: Communication skills training with web-enabled video feedback and a Question Prompt Sheet (QPS)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Question Prompt Sheet (QPS)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Experimental group (communication skills training)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 210
Study: 19226611

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy and hypnosis (CBTH)
Number of subjects: 40
Study: 18004255

Group type: EXPERIMENTAL
Intervention: TIKLO (250 mg, BID)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Thrombo ASS (100 mg, QD)
Number of subjects: 63
Study: 15209688

Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 112
Study: 11239527

Group type: EXPERIMENTAL
Intervention: HOST-selected live spermatozoa
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-HOST (nonselected sperm)
Number of subjects: 30
Study: 9740439

Group type: COMPARATOR
Intervention: Standard swim-up semen preparation (Group A)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Swim-up followed by test yolk buffer incubation (Group B)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard swim-up (male factor group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Swim-up and TYB incubation (male factor group)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard swim-up (unexplained infertility group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Swim-up and TYB incubation (unexplained infertility group)
Number of subjects: 121
Study: 7914611

Group type: EXPERIMENTAL
Intervention: 300 mg/day amiodarone
Number of subjects: 516

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 516
Study: 3054011

Group type: EXPERIMENTAL
Intervention: Piperacillin (broad-spectrum antibiotic) given as three perioperative doses, each 6 hours apart.
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo given as three perioperative doses, each 6 hours apart.
Number of subjects: 417
Study: 30677780

Group type: EXPERIMENTAL
Intervention: Group intervention consisting of eight sessions led by a psychotherapist and a former head and neck cancer patient (peer)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Socio-legal counselling
Number of subjects: 113
Study: 29231471

Group type: EXPERIMENTAL
Intervention: Penetration acupuncture at Baxie (EX‐UE 9) combined with rehabilitation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple rehabilitation
Number of subjects: 60
Study: 25225715

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBV)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 23510493

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg for 6 weeks, then increased to 10 mg till week 12, then hydrochlorothiazide 25 mg added
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg till week 6, then amlodipine 5‐10 mg added
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Amlodipine 5‐10 mg + hydrochlorothiazide 25 mg
Number of subjects: 90
Study: 21330846

Group type: EXPERIMENTAL
Intervention: Dichotomous checklist for performance rating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global Performance Assessment Tool (GPAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both instruments (checklist and GPAT)
Number of subjects: 0
Study: 19060022

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg twice daily)
Number of subjects: 40
Study: 16861943

Group type: EXPERIMENTAL
Intervention: Daclizumab + Mycophenolate mofetil + Prednisolone (Dac-group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cyclosporine A + Mycophenolate mofetil + Prednisolone (CsA-group)
Number of subjects: 54
Study: 14748819

Group type: EXPERIMENTAL
Intervention: High-carbohydrate high-calorie diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat high-calorie diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced normal calorie diet
Number of subjects: 0
Study: 11690571

Group type: EXPERIMENTAL
Intervention: Plasma fibrinogen levels (baseline <314 mg/dL)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Plasma fibrinogen levels (314 to 373 mg/dL)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Plasma fibrinogen levels (>373 mg/dL)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Upper tertile of fibrinogen levels (>373 mg/dL)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Change in fibrinogen from baseline
Number of subjects: 176
Study: 10771931

Group type: EXPERIMENTAL
Intervention: Thalassemic children
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Thalassemic children with hemoglobin levels < 8 gm/dl
Number of subjects: 233

Group type: COMPARATOR
Intervention: Non-thalassemic siblings
Number of subjects: 233
Study: 7875187

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate extended-release (ISDN-ER) 10 mg immediate release and 60 mg slow release
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate extended-release (ISDN-ER)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate extended-release (ISDN-ER) after 14 days of treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic measurements of ISDN
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ISDN before drug after 14 days of treatment
Number of subjects: 8
Study: 3359122

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment only for reflux grade III or less
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Surgery plus antibiotic treatment for reflux grade IV
Number of subjects: 95

Group type: COMPARATOR
Intervention: Antibiotic treatment alone for reflux grade IV
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Reimplantation for reflux grade V
Number of subjects: 95
Study: 29426348

Group type: EXPERIMENTAL
Intervention: Real acupuncture (semi-individualized acupuncture points)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture (minimal acupuncture on non-acupuncture points)
Number of subjects: 0
Study: 27255763

Group type: EXPERIMENTAL
Intervention: Luseogliflozin
Number of subjects: 34
Study: 25982108

Group type: EXPERIMENTAL
Intervention: Ongoing GDMT plus Baroreflex Activation Therapy (BAT) for 6 months
Number of subjects: 146

Group type: COMPARATOR
Intervention: Ongoing GDMT alone for 6 months
Number of subjects: 146
Study: 23676933

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) suspension
Number of subjects: 118

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) tablets
Number of subjects: 118
Study: 20233196

Group type: EXPERIMENTAL
Intervention: S-0139 (15 μg kg-1 min-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S-0139 (15.7 μg kg-1 min-1) in delayed administration study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S-0139 (2.5 μg kg-1 min-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S-0139 (6.67 μg kg-1 min-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S-0139 (0.08-13.33 μg kg-1 min-1) in pilot study
Number of subjects: 0
Study: 18184294

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 30
Study: 16496208

Group type: EXPERIMENTAL
Intervention: Double IUI (two inseminations 18-24 and 36-48 hours post hCG injection)
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Single IUI (one insemination 34 hours post hCG administration)
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Single IUI in male factor infertility (M(1))
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: Double IUI in male factor infertility (M(2))
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Single IUI in idiopathic infertility (I(1))
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: Double IUI in idiopathic infertility (I(2))
Number of subjects: 1270